Aimee Ginsburg, PharmD, BCPS; Kaci Dominguez, PharmD; Leslie T. Busby, MD; Josh Howell, PharmD, BCOP
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Aimee Ginsburg, PharmD, BCPS, and colleagues argue that atezolizumab plus bevacizumab is cost-effective when compared with sorafenib under current pricing, despite contradicting findings from a study presented at ASCO 2021.
Aimee Ginsburg, PharmD, BCPS,...
